Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2015 | 03-2014 | 03-2013 | 03-2012 | 03-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,301,609 | 1,095,580 | 1,569,450 | 3,206,470 | 4,476,770 |
| Depreciation Amortization | 2,374,654 | 2,157,430 | 2,433,380 | 1,625,180 | 11,325,800 |
| Accounts receivable | -295,887 | -425,040 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -64,446 | 23,060 | N/A | N/A | N/A |
| Other Working Capital | 1,658,985 | -124,820 | 149,180 | 822,000 | -110,360 |
| Other Operating Activity | -710,792 | -1,242,860 | -428,740 | -1,379,220 | -11,753,200 |
| Operating Cash Flow | $1,660,905 | $1,483,350 | $3,723,270 | $4,274,430 | $3,939,010 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -130,394 | -367,420 | -848,520 | -518,740 | -1,487,650 |
| Net Acquisitions | N/A | -33,420 | -977,880 | 0 | 0 |
| Purchase Of Investment | -32,496 | -1,416,860 | N/A | N/A | N/A |
| Sale Of Investment | 1,504,749 | 522,690 | N/A | N/A | N/A |
| Purchase Sale Intangibles | -550,423 | -284,110 | N/A | N/A | N/A |
| Other Investing Activity | -510,601 | -291,100 | 478,760 | -13,374,600 | 291,810 |
| Investing Cash Flow | $831,258 | $-1,586,110 | $-1,347,640 | $-13,893,340 | $-1,195,840 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | -1,086,813 | 2,496,810 | N/A | N/A | N/A |
| Debt Repayment | -573 | -1,670 | N/A | N/A | N/A |
| Common Stock Repurchased | -160,042 | N/A | N/A | N/A | N/A |
| Dividend Paid | -1,288,897 | -1,421,330 | -1,719,620 | -1,803,560 | -1,711,500 |
| Other Financing Activity | -202,757 | -59,400 | -102,140 | 6,804,680 | -54,090 |
| Financing Cash Flow | $-2,739,082 | $1,014,410 | $-1,821,760 | $5,001,120 | $-1,765,590 |
| Exchange Rate Effect | 148,594 | 293,030 | 551,250 | -696,700 | -733,840 |
| Beginning Cash Position | 6,061,037 | 5,455,800 | 5,496,380 | 11,083,410 | 10,270,840 |
| End Cash Position | 5,962,711 | 6,660,480 | 6,601,510 | 5,768,930 | 10,514,570 |
| Net Cash Flow | $-98,326 | $1,204,670 | $1,105,120 | $-5,314,480 | $243,730 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,660,905 | 1,483,350 | 3,723,270 | 4,274,430 | 3,939,010 |
| Capital Expenditure | -438,911 | -501,080 | N/A | N/A | N/A |
| Free Cash Flow | 1,221,994 | 982,270 | 3,723,270 | 4,274,430 | 3,939,010 |